{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:04:33Z","timestamp":1783400673997,"version":"3.54.6"},"reference-count":95,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>&lt;p&gt;Parkinson\u2019s disease (PD) is the second most common progressive neurodegenerative disease\nworldwide and presents as a progressive motor disorder. Gene mutations play a pivotal role in\nthe degeneration of dopaminergic neurons in the substantia nigra region. Mutations in the Leucine\nrich repeat kinase 2 (LRRK2) gene have been identified as one of the most common genetic causes\nof PD. LRRK2 is a multi-functional protein involved in several critical cellular processes, including\nmitochondrial function, autophagy, vesicular trafficking, and immune system regulation. Dysregulation\nof these processes due to aberrant LRRK2 activity contributes to neuronal degeneration, particularly\nin dopaminergic neurons, which are most affected in PD. The current review discusses the\nstructure of LRRK2, its function, and pathogenic mutations in the context of PD. However, significant\nchallenges remain, particularly in terms of ensuring drug specificity, minimizing off-target effects,\nand understanding the long-term safety and efficacy of these treatments. As we advance our\nunderstanding of LRRK2 biology, it remains a highly promising target for therapeutic strategies\naimed at modifying the course of Parkinson\u2019s disease.&lt;\/p&gt;<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118715273377507250320035243","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T06:12:11Z","timestamp":1744697531000},"page":"823-832","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring LRRK2-dependent Mechanisms in Parkinson\u2019s Disease Therapy"],"prefix":"10.2174","volume":"24","author":[{"given":"Veerta","family":"Sharma","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwali","family":"Sharma","sequence":"additional","affiliation":[{"name":"Chitkara University School of Pharmacy, Chitkara University, Himachal Pradesh, 174103, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareen","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"Morris H.R.","year":"2024","unstructured":"Morris H.R.; Spillantini M.G.; Sue C.M.; Williams-Gray C.H.; The pathogenesis of Parkinson\u2019s disease. Lancet  2024,403(10423),293-304","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s43440-024-00613-5","volume":"76","author":"Sharma V.","year":"2024","unstructured":"Sharma V.; Sharma P.; Singh T.G.; Mechanistic insights on TLR-4 mediated inflammatory pathway in neurodegenerative diseases. Pharmacol Rep  2024,76(4),679-692","journal-title":"Pharmacol Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11011-024-01452-2","volume":"40","author":"Sharma V.","year":"2024","unstructured":"Sharma V.; Sharma P.; Singh T.G.; Emerging role of Nrf2 in Parkinson\u2019s disease therapy: A critical reassessment. Metab Brain Dis  2024,40(1),70","journal-title":"Metab Brain Dis"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"Ramesh S.","year":"2023","unstructured":"Ramesh S.; Arachchige A.S.P.M.; Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: A review of the literature. AIMS Neurosci  2023,10(3),200-231","journal-title":"AIMS Neurosci"},{"key":"ref=5","first-page":"25","author":"El-Mansoury B.","year":"2023","unstructured":"El-Mansoury B.; Maloui A.B.; Draoui A.; Non-Motor Symptoms in Parkinson\u2019s Disease: The Other Side of the Disease. In: Experimental and Clinical Evidence of the Neuropathology of Parkinson\u2019s Disease  2023,25-45","journal-title":"In: Experimental and Clinical Evidence of the Neuropathology of Parkinson\u2019s Disease"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"S275","DOI":"10.3233\/JPD-230348","volume":"14","author":"Orso B.","year":"2024","unstructured":"Orso B.; Brosse S.; Frasnelli J.; Arnaldi D.; Opportunities and pitfalls of REM sleep behavior disorder and olfactory dysfunction as early markers in parkinson\u2019s disease. J Parkinsons Dis  2024,14(s2),S275-S282","journal-title":"J Parkinsons Dis"},{"key":"ref=7","author":"Bandres-Ciga S.","year":"2020","unstructured":"Bandres-Ciga S.; Saez-Atienzar S.; Kim J.J.; Large-scale pathway-specific polygenic risk, transcriptomic community networks and functional inferences in Parkinson disease. bioRxiv  2020","journal-title":"bioRxiv"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"971270","DOI":"10.3389\/fnins.2022.971270","volume":"16","author":"Turski P.","year":"2022","unstructured":"Turski P.; Chaberska I.; Szuka\u0142o P.; Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson\u2019s disease. Front Neurosci  2022,16,971270","journal-title":"Front Neurosci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.3390\/cells9122565","volume":"9","author":"Jeong G.R.","year":"2020","unstructured":"Jeong G.R.; Lee B.D.; Pathological functions of LRRK2 in Parkinson\u2019s disease. Cells  2020,9(12),2565","journal-title":"Cells"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jnc.12949","volume":"131","author":"Martin I.","year":"2014","unstructured":"Martin I.; Kim J.W.; Dawson V.L.; Dawson T.M.; LRRK2 pathobiology in Parkinson\u2019s disease. J Neurochem  2014,131(5),554-565","journal-title":"J Neurochem"},{"key":"ref=11","author":"Wu C.","year":"2019","unstructured":"Wu C.;  Structure and Function of the G Domain of Parkinson\u2019s Disease-associated Protein LRRK2  2019","journal-title":"Structure and Function of the G Domain of Parkinson\u2019s Disease-associated Protein LRRK2"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.molmed.2024.07.003","volume":"30","author":"Xiong Y.","year":"2024","unstructured":"Xiong Y.; Yu J.; LRRK2 in Parkinson\u2019s disease: Upstream regulation and therapeutic targeting. Trends Mol Med  2024,30(10),982-996","journal-title":"Trends Mol Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.3390\/ijms22042007","volume":"22","author":"Liskova A.","year":"2021","unstructured":"Liskova A.; Samec M.; Koklesova L.; Kudela E.; Kubatka P.; Golubnitschaja O.; Mitochondriopathies as a clue to systemic disorders\u2014analytical tools and mitigating measures in context of predictive, preventive, and personalized (3P) medicine. Int J Mol Sci  2021,22(4),2007","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuroscience.2014.10.028","volume":"302","author":"Dzamko N.","year":"2015","unstructured":"Dzamko N.; Geczy C.L.; Halliday G.M.; Inflammation is genetically implicated in Parkinson\u2019s disease. Neuroscience  2015,302,89-102","journal-title":"Neuroscience"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.3390\/antiox11091634","volume":"11","author":"Filippone A.","year":"2022","unstructured":"Filippone A.; Mannino D.; Cucinotta L.; Paterniti I.; Esposito E.; Campolo M.; LRRK2 inhibition by PF06447475 antagonist modulates early neuronal damage after spinal cord trauma. Antioxidants  2022,11(9),1634","journal-title":"Antioxidants"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JPD-130192","volume":"3","author":"Pais\u00e1n-Ruiz C.","year":"2013","unstructured":"Pais\u00e1n-Ruiz C.; Lewis P.A.; Singleton A.B.; LRRK2: Cause, risk, and mechanism. J Parkinsons Dis  2013,3(2),85-103","journal-title":"J Parkinsons Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1074\/jbc.M113.537811","volume":"289","author":"Ray S.","year":"2014","unstructured":"Ray S.; Bender S.; Kang S.; Lin R.; Glicksman M.A.; Liu M.; The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity. J Biol Chem  2014,289(19),13042-13053","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/hmg\/dds522","volume":"22","author":"Biosa A.","year":"2013","unstructured":"Biosa A.; Trancikova A.; Civiero L.; GTPase activity regulates kinase activity and cellular phenotypes of Parkinson\u2019s disease-associated LRRK2. Hum Mol Genet  2013,22(6),1140-1156","journal-title":"Hum Mol Genet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1073\/pnas.1323285111","volume":"111","author":"Liao J.","year":"2014","unstructured":"Liao J.; Wu C.X.; Burlak C.; Parkinson disease-associated mutation R1441H in LRRK2 prolongs the \u201cactive state\u201d of its GTPase domain. Proc Natl Acad Sci USA  2014,111(11),4055-4060","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13024-018-0240-1","volume":"13","author":"Jeong G.R.","year":"2018","unstructured":"Jeong G.R.; Jang E.H.; Bae J.R.; Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Mol Neurodegener  2018,13(1),8","journal-title":"Mol Neurodegener"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"16959","DOI":"10.1523\/JNEUROSCI.1807-10.2010","volume":"30","author":"Lee S.","year":"2010","unstructured":"Lee S.; Liu H.P.; Lin W.Y.; Guo H.; Lu B.; LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci  2010,30(50),16959-16969","journal-title":"J Neurosci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1471-4159.2012.07809.x","volume":"122","author":"Niu J.","year":"2012","unstructured":"Niu J.; Yu M.; Wang C.; Xu Z.; Leucine\u2010rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin\u2010like protein. J Neurochem  2012,122(3),650-658","journal-title":"J Neurochem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/hmg\/dds003","volume":"21","author":"Wang X.","year":"2012","unstructured":"Wang X.; Yan M.H.; Fujioka H.; LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet  2012,21(9),1931-1944","journal-title":"Hum Mol Genet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1021\/cb2002413","volume":"6","author":"Ramsden N.","year":"2011","unstructured":"Ramsden N.; Perrin J.; Ren Z.; Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson\u2019s disease-related toxicity in human neurons. ACS Chem Biol  2011,6(10),1021-1028","journal-title":"ACS Chem Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/hmg\/ddt061","volume":"22","author":"Hindle S.","year":"2013","unstructured":"Hindle S.; Afsari F.; Stark M.; Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy. Hum Mol Genet  2013,22(11),2129-2140","journal-title":"Hum Mol Genet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.nbd.2010.04.002","volume":"40","author":"Yao C.","year":"2010","unstructured":"Yao C.; Khoury E.R.; Wang W.; LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson\u2019s disease. Neurobiol Dis  2010,40(1),73-81","journal-title":"Neurobiol Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1093\/hmg\/ddr312","volume":"20","author":"Liu Z.","year":"2011","unstructured":"Liu Z.; Hamamichi S.; Lee D.B.; Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson\u2019s disease models. Hum Mol Genet  2011,20(20),3933-3942","journal-title":"Hum Mol Genet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2015.02.019","volume":"77","author":"Tsika E.","year":"2015","unstructured":"Tsika E.; Nguyen A.P.T.; Dusonchet J.; Colin P.; Schneider B.L.; Moore D.J.; Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson\u2019s disease. Neurobiol Dis  2015,77,49-61","journal-title":"Neurobiol Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.nbd.2014.04.021","volume":"68","author":"Chou J.S.","year":"2014","unstructured":"Chou J.S.; Chen C.Y.; Chen Y.L.; (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Neurobiol Dis  2014,68,190-199","journal-title":"Neurobiol Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.expneurol.2015.09.001","volume":"275","author":"Weng Y.H.","year":"2016","unstructured":"Weng Y.H.; Chen C.Y.; Lin K.J.; (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model. Exp Neurol  2016,275(Pt 1),104-115","journal-title":"Exp Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1073\/pnas.1712648115","volume":"115","author":"Xiong Y.","year":"2018","unstructured":"Xiong Y.; Neifert S.; Karuppagounder S.S.; Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci USA  2018,115(7),1635-1640","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-017-0426-8","volume":"5","author":"Longo F.","year":"2017","unstructured":"Longo F.; Mercatelli D.; Novello S.; Age-dependent dopamine transporter dysfunction and Serine129 phospho-\u03b1-synuclein overload in G2019S LRRK2 mice. Acta Neuropathol Commun  2017,5(1),22","journal-title":"Acta Neuropathol Commun"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1750-1326-7-15","volume":"7","author":"Maekawa T.","year":"2012","unstructured":"Maekawa T.; Mori S.; Sasaki Y.; The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener  2012,7(1),15","journal-title":"Mol Neurodegener"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e70249","DOI":"10.1371\/journal.pone.0070249","volume":"8","author":"Bichler Z.","year":"2013","unstructured":"Bichler Z.; Lim H.C.; Zeng L.; Tan E.K.; Non-motor and motor features in LRRK2 transgenic mice. PLoS One  2013,8(7),e70249","journal-title":"PLoS One"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.neuron.2012.08.022","volume":"75","author":"Matta S.","year":"2012","unstructured":"Matta S.; Kolen V.K.; Cunha D.R.; LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron  2012,75(6),1008-1021","journal-title":"Neuron"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7555\/JBR.31.20170039","volume":"32","author":"Min F.","year":"2018","unstructured":"Min F.; Xin H.; Na L.; Distinctive roles of Rac1 and Rab29 in LRRK2 mediated membrane trafficking and neurite outgrowth. J Biomed Res  2018,32(2),145-156","journal-title":"J Biomed Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"16140","DOI":"10.1074\/jbc.M111.234005","volume":"286","author":"Chan D.","year":"2011","unstructured":"Chan D.; Citro A.; Cordy J.M.; Shen G.C.; Wolozin B.; Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J Biol Chem  2011,286(18),16140-16149","journal-title":"J Biol Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e31012","DOI":"10.7554\/eLife.31012","volume":"6","author":"Steger M.","year":"2017","unstructured":"Steger M.; Diez F.; Dhekne H.S.; Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife  2017,6,e31012","journal-title":"Elife"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.celrep.2017.10.011","volume":"21","author":"Li C.","year":"2017","unstructured":"Li C.; Wei Z.; Fan Y.; The GTPase Rab43 controls the anterograde ER-Golgi trafficking and sorting of GPCRs. Cell Rep  2017,21(4),1089-1101","journal-title":"Cell Rep"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1093\/hmg\/ddu202","volume":"23","author":"Dusonchet J.","year":"2014","unstructured":"Dusonchet J.; Li H.; Guillily M.; A Parkinson\u2019s disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. Hum Mol Genet  2014,23(18),4887-4905","journal-title":"Hum Mol Genet"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cell.2014.01.064","volume":"157","author":"Martin I.","year":"2014","unstructured":"Martin I.; Kim J.W.; Lee B.D.; Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson\u2019s disease. Cell  2014,157(2),472-485","journal-title":"Cell"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e30834","DOI":"10.1371\/journal.pone.0030834","volume":"7","author":"Kawakami F.","year":"2012","unstructured":"Kawakami F.; Yabata T.; Ohta E.; LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One  2012,7(1),e30834","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"Tolosa E.","year":"2020","unstructured":"Tolosa E.; Vila M.; Klein C.; Rascol O.; LRRK2 in Parkinson disease: Challenges of clinical trials. Nat Rev Neurol  2020,16(2),97-107","journal-title":"Nat Rev Neurol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","volume":"432","author":"Hou X.","year":"2020","unstructured":"Hou X.; Watzlawik J.O.; Fiesel F.C.; Springer W.; Autophagy in Parkinson\u2019s disease. J Mol Biol  2020,432(8),2651-2672","journal-title":"J Mol Biol"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1002\/9781118978320","author":"Maxfield F.R.","year":"2016","unstructured":"Maxfield F.R.; Willard J.M.; Lu S.;  Lysosomes: Biology, diseases, and therapeutics  2016","journal-title":"Lysosomes: Biology, diseases, and therapeutics"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-319-49969-7_5","volume":"14","author":"Manzoni C.","year":"2017","unstructured":"Manzoni C.; Lewis P.A.; LRRK2 and autophagy. Adv Neurobiol  2017,14,89-105","journal-title":"Adv Neurobiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/10738584241232963","volume":"30","author":"Zalon A.J.","year":"2024","unstructured":"Zalon A.J.; Quiriconi D.J.; Pitcairn C.; Mazzulli J.R.; \u03b1-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson\u2019s disease. Neuroscientist  2024,30(5),612-635","journal-title":"Neuroscientist"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/brain\/awy077","volume":"141","author":"Kozina E.","year":"2018","unstructured":"Kozina E.; Sadasivan S.; Jiao Y.; Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. Brain  2018,141(6),1753-1769","journal-title":"Brain"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"13033","DOI":"10.3390\/ijms241713033","volume":"24","author":"Grel H.","year":"2023","unstructured":"Grel H.; Woznica D.; Ratajczak K.; Mitochondrial dynamics in neurodegenerative diseases: Unraveling the role of fusion and fission processes. Int J Mol Sci  2023,24(17),13033","journal-title":"Int J Mol Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/antiox6020025","volume":"6","author":"Gao J.","year":"2017","unstructured":"Gao J.; Wang L.; Liu J.; Xie F.; Su B.; Wang X.; Abnormalities of mitochondrial dynamics in neurodegenerative diseases. Antioxidants  2017,6(2),25","journal-title":"Antioxidants"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"32368","DOI":"10.1007\/s11356-022-19082-5","volume":"29","author":"Kumar S.","year":"2022","unstructured":"Kumar S.; Behl T.; Sehgal A.; Exploring the focal role of LRRK2 kinase in Parkinson\u2019s disease. Environ Sci Pollut Res Int  2022,29(22),32368-32382","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=52","author":"Yong-Kee C.","year":"2013","unstructured":"Yong-Kee C.; Determination of the sub-cellular mechanisms underlying neurodegeneration in parkinson\u2019s disease. Thesis, Doctoral dissertation  2013","journal-title":"Thesis, Doctoral dissertation"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/BST20180464","volume":"47","author":"Harvey K.","year":"2019","unstructured":"Harvey K.; Outeiro T.F.; The role of LRRK2 in cell signalling. Biochem Soc Trans  2019,47(1),197-207","journal-title":"Biochem Soc Trans"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3390\/genes12040505","volume":"12","author":"Hur E.M.","year":"2021","unstructured":"Hur E.M.; Lee B.D.; LRRK2 at the crossroad of aging and parkinson\u2019s disease. Genes  2021,12(4),505","journal-title":"Genes"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3389\/fneur.2020.00881","volume":"11","author":"Delcambre S.","year":"2020","unstructured":"Delcambre S.; Ghelfi J.; Ouzren N.; Mitochondrial mechanisms of LRRK2 G2019S penetrance. Front Neurol  2020,11,881","journal-title":"Front Neurol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3934\/Neuroscience.2020004","volume":"7","author":"Theocharopoulou G.","year":"2020","unstructured":"Theocharopoulou G.; The ubiquitous role of mitochondria in Parkinson and other neurodegenerative diseases. AIMS Neurosci  2020,7(1),43-65","journal-title":"AIMS Neurosci"},{"key":"ref=57","author":"Ku\u00df M.","unstructured":"Ku\u00df M.; Interferon gamma induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5. Thesis, Doctoral dissertation, University of T\u00fcbingen","journal-title":"Thesis, Doctoral dissertation, University of T\u00fcbingen"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1042\/BST20180463","volume":"47","author":"Wallings R.L.","year":"2019","unstructured":"Wallings R.L.; Tansey M.G.; LRRK2 regulation of immune-pathways and inflammatory disease. Biochem Soc Trans  2019,47(6),1581-1595","journal-title":"Biochem Soc Trans"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"105070","DOI":"10.1016\/j.neuint.2021.105070","volume":"147","author":"Nazish I.","year":"2021","unstructured":"Nazish I.; Arber C.; Piers T.M.; Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells. Neurochem Int  2021,147,105070","journal-title":"Neurochem Int"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.2174\/1570159X16666180222165418","volume":"16","author":"Rui Q.","year":"2018","unstructured":"Rui Q.; Ni H.; Li D.; Gao R.; Chen G.; The role of LRRK2 in neurodegeneration of Parkinson disease. Curr Neuropharmacol  2018,16(9),1348-1357","journal-title":"Curr Neuropharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-981-13-9913-8_13","volume":"1175","author":"Ho M.S.","year":"2019","unstructured":"Ho M.S.; Microglia in Parkinson\u2019s disease. Adv Exp Med Biol  2019,1175,335-353","journal-title":"Adv Exp Med Biol"},{"key":"ref=62","author":"Almudimeegh S.","unstructured":"Almudimeegh S.; Modulation of LRRK2 mediated signaling in immune cells. Thesis, Doctoral dissertation, UCL (University College London","journal-title":"Thesis, Doctoral dissertation, UCL (University College London"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"104626","DOI":"10.1016\/j.nbd.2019.104626","volume":"134","author":"Rocha E.M.","year":"2020","unstructured":"Rocha E.M.; Miranda D.B.R.; Castro S.; LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson\u2019s disease. Neurobiol Dis  2020,134,104626","journal-title":"Neurobiol Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/glia.23571","volume":"67","author":"Yang Q.","year":"2019","unstructured":"Yang Q.; Zhou J.; Neuroinflammation in the central nervous system: Symphony of glial cells. Glia  2019,67(6),1017-1035","journal-title":"Glia"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3390\/ma15030804","volume":"15","author":"Bhattacharya T.","year":"2022","unstructured":"Bhattacharya T.; Soares G.A.B.; Chopra H.; Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders. Materials  2022,15(3),804","journal-title":"Materials"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"8421","DOI":"10.3390\/ijms21228421","volume":"21","author":"Marogianni C.","year":"2020","unstructured":"Marogianni C.; Sokratous M.; Dardiotis E.; Hadjigeorgiou G.M.; Bogdanos D.; Xiromerisiou G.; Neurodegeneration and inflammation\u2014an interesting interplay in Parkinson\u2019s disease. Int J Mol Sci  2020,21(22),8421","journal-title":"Int J Mol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"Tansey M.G.","year":"2022","unstructured":"Tansey M.G.; Wallings R.L.; Houser M.C.; Herrick M.K.; Keating C.E.; Joers V.; Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol  2022,22(11),657-673","journal-title":"Nat Rev Immunol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.3390\/ijms22115818","volume":"22","author":"Harry G.J.","year":"2021","unstructured":"Harry G.J.; Microglia in neurodegenerative events\u2014an initiator or a significant other? Int J Mol Sci  2021,22(11),5818","journal-title":"Int J Mol Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"105094","DOI":"10.1016\/j.neuint.2021.105094","volume":"148","author":"Zheng T.","year":"2021","unstructured":"Zheng T.; Zhang Z.; Activated microglia facilitate the transmission of \u03b1-synuclein in Parkinson\u2019s disease. Neurochem Int  2021,148,105094","journal-title":"Neurochem Int"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00702-011-0653-2","volume":"118","author":"Hakimi M.","year":"2011","unstructured":"Hakimi M.; Selvanantham T.; Swinton E.; Parkinson\u2019s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm  2011,118(5),795-808","journal-title":"J Neural Transm"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e21519","DOI":"10.1371\/journal.pone.0021519","volume":"6","author":"Th\u00e9venet J.","year":"2011","unstructured":"Th\u00e9venet J.; Gobert P.R.; Hooft van Huijsduijnen R.; Wiessner C.; Sagot Y.J.; Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One  2011,6(6),e21519","journal-title":"PLoS One"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1523\/JNEUROSCI.5601-11.2012","volume":"32","author":"Moehle M.S.","year":"2012","unstructured":"Moehle M.S.; Webber P.J.; Tse T.; LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci  2012,32(5),1602-1611","journal-title":"J Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neuroscience.2012.02.001","volume":"208","author":"Gillardon F.","year":"2012","unstructured":"Gillardon F.; Schmid R.; Draheim H.; Parkinson\u2019s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience  2012,208,41-48","journal-title":"Neuroscience"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/glia.22437","volume":"61","author":"Fellner L.","year":"2013","unstructured":"Fellner L.; Irschick R.; Schanda K.; Toll\u2010like receptor 4 is required for \u03b1\u2010synuclein dependent activation of microglia and astroglia. Glia  2013,61(3),349-360","journal-title":"Glia"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"Kim C.","year":"2013","unstructured":"Kim C.; Ho D.H.; Suk J.E.; Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun  2013,4(1),1562","journal-title":"Nat Commun"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-022-00297-9","volume":"8","author":"Rastegar A.D.","year":"2022","unstructured":"Rastegar A.D.; Hughes L.P.; Perera G.; Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinsons Dis  2022,8(1),34","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12868-016-0315-2","volume":"17","author":"Maekawa T.","year":"2016","unstructured":"Maekawa T.; Sasaoka T.; Azuma S.; Leucine-rich repeat kinase 2 (LRRK2) regulates \u03b1-synuclein clearance in microglia. BMC Neurosci  2016,17(1),77","journal-title":"BMC Neurosci"},{"key":"ref=78","first-page":"49","volume":"1","author":"Ahn T.B.","year":"2012","unstructured":"Ahn T.B.; Langston J.W.; Aachi V.R.; Dickson D.W.; Relationship of neighboring tissue and gliosis to \u03b1-synuclein pathology in a fetal transplant for Parkinson\u2019s disease. Am J Neurodegener Dis  2012,1(1),49-59","journal-title":"Am J Neurodegener Dis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12035-012-8340-3","volume":"47","author":"Fellner L.","year":"2013","unstructured":"Fellner L.; Stefanova N.; The role of glia in \u03b1-synucleinopathies. Mol Neurobiol  2013,47(2),575-586","journal-title":"Mol Neurobiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"71","DOI":"10.31887\/DCNS.2017.19.1\/rpal","volume":"19","author":"Tiwari P.C.","year":"2017","unstructured":"Tiwari P.C.; Pal R.; The potential role of neuroinflammation and transcription factors in Parkinson disease. Dialogues Clin Neurosci  2017,19(1),71-80","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12974-015-0449-7","volume":"12","author":"Russo I.","year":"2015","unstructured":"Russo I.; Berti G.; Plotegher N.; Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-\u03baB p50 signaling in cultured microglia cells. J Neuroinflammation  2015,12(1),230","journal-title":"J Neuroinflammation"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbrc.2016.11.163","volume":"482","author":"Ho D.H.","year":"2017","unstructured":"Ho D.H.; Seol W.; Eun J.H.; Son I.; Phosphorylation of p53 by LRRK2 induces microglial tumor necrosis factor \u03b1-mediated neurotoxicity. Biochem Biophys Res Commun  2017,482(4),1088-1094","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"11744","DOI":"10.3390\/ijms231911744","volume":"23","author":"Ravinther A.I.","year":"2022","unstructured":"Ravinther A.I.; Dewadas H.D.; Tong S.R.; Molecular pathways involved in LRRK2-linked Parkinson\u2019s disease: A systematic review. Int J Mol Sci  2022,23(19),11744","journal-title":"Int J Mol Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12974-016-0588-5","volume":"13","author":"Brockmann K.","year":"2016","unstructured":"Brockmann K.; Apel A.; Schulte C.; Inflammatory profile in LRRK2-associated prodromal and clinical PD. J Neuroinflammation  2016,13(1),122","journal-title":"J Neuroinflammation"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/jnc.12483","volume":"128","author":"Luerman G.C.","year":"2014","unstructured":"Luerman G.C.; Nguyen C.; Samaroo H.; Phosphoproteomic evaluation of pharmacological inhibition of leucine\u2010 rich repeat kinase 2 reveals significant off\u2010target effects of LRRK \u20102\u2010 IN \u20101. J Neurochem  2014,128(4),561-576","journal-title":"J Neurochem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11557","volume":"491","author":"Liu G.H.","year":"2012","unstructured":"Liu G.H.; Qu J.; Suzuki K.; Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature  2012,491(7425),603-607","journal-title":"Nature"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/embj.201798099","volume":"37","author":"Purlyte E.","year":"2018","unstructured":"Purlyte E.; Dhekne H.S.; Sarhan A.R.; Rab29 activation of the Parkinson\u2019s disease\u2010associated LRRK2 kinase. EMBO J  2018,37(1),1-18","journal-title":"EMBO J"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14728222.2017.1323881","volume":"21","author":"Chan S.L.","year":"2017","unstructured":"Chan S.L.; Tan E.K.; Targeting LRRK2 in Parkinson\u2019s disease: An update on recent developments. Expert Opin Ther Targets  2017,21(6),601-610","journal-title":"Expert Opin Ther Targets"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1021\/jm401654j","volume":"57","author":"Estrada A.A.","year":"2014","unstructured":"Estrada A.A.; Chan B.K.; Baker-Glenn C.; Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem  2014,57(3),921-936","journal-title":"J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/ml300123a","volume":"3","author":"Choi H.G.","year":"2012","unstructured":"Choi H.G.; Zhang J.; Deng X.; Brain penetrant LRRK2 inhibitor. ACS Med Chem Lett  2012,3(8),658-662","journal-title":"ACS Med Chem Lett"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1021\/acsmedchemlett.5b00064","volume":"6","author":"Hatcher J.M.","year":"2015","unstructured":"Hatcher J.M.; Zhang J.; Choi H.G.; Ito G.; Alessi D.R.; Gray N.S.; Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor. ACS Med Chem Lett  2015,6(5),584-589","journal-title":"ACS Med Chem Lett"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"9416","DOI":"10.1021\/jm301020q","volume":"55","author":"Estrada A.A.","year":"2012","unstructured":"Estrada A.A.; Liu X.; Baker-Glenn C.; Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem  2012,55(22),9416-9433","journal-title":"J Med Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"273ra15","DOI":"10.1126\/scitranslmed.aaa3634","volume":"7","author":"Fuji R.N.","year":"2015","unstructured":"Fuji R.N.; Flagella M.; Baca M.; Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med  2015,7(273),273ra15","journal-title":"Sci Transl Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/jm5014055","volume":"58","author":"Henderson J.L.","year":"2015","unstructured":"Henderson J.L.; Kormos B.L.; Hayward M.M.; Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem  2015,58(1),419-432","journal-title":"J Med Chem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"Fell M.J.","year":"2015","unstructured":"Fell M.J.; Mirescu C.; Basu K.; MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther  2015,355(3),397-409","journal-title":"J Pharmacol Exp Ther"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715273377507250320035243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/241019\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715273377507250320035243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:45:15Z","timestamp":1761547515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/241019\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":95,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715273377507250320035243","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}